Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05109702 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution in Participants With Dry Eye
A Phase 3 study, sponsored by HanAll BioPharma Co..
- Completed
- Registry status
- Phase 3
- Development phase
- 260
- Enrollment target
NCT05109702 is a Phase 3 study that has completed, run by HanAll BioPharma Co.. The registered enrollment target is 260 participants.
The verdict
NCT05109702, a Phase 3 study, has completed, sponsored by HanAll BioPharma Co..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 260 participants
- Enrollment target
Study Summary
The objective of this study was to compare the safety and efficacy of tanfanercept ophthalmic solution 0.25% with placebo for the treatment of the signs and symptoms of dry eye.
Interventions
- DRUG Placebo
- DRUG 0.25% Tanfanercept Ophthalmic Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2021-11-18 |
| Est. Completion | 2022-05-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05109702
The ClinicalTrials.gov registry entry for NCT05109702 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HanAll BioPharma Co., which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05109702 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05109702 about?
NCT05109702 is a clinical study titled "A Study to Assess the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution in Participants With Dry Eye". The objective of this study was to compare the safety and efficacy of tanfanercept ophthalmic solution 0.25% with placebo for the treatment of the signs and symptoms of dry eye.
What is the current status of trial NCT05109702?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 260 participants. The study started on 2021-11-18. Estimated completion is 2022-05-06.
What interventions are being tested in trial NCT05109702?
The interventions under investigation include: Placebo (DRUG), 0.25% Tanfanercept Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT05109702?
This trial is sponsored by HanAll BioPharma Co., which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.